Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akums Drugs and Pharmaceuticals Limited ( (IN:AKUMS) ) has shared an announcement.
Akums Drugs and Pharmaceuticals Limited has been granted a patent for its innovative Dual Release Gastro-Resistant Composition, a next-generation proton pump inhibitor (PPI) tablet designed to treat gastroesophageal reflux disease (GERD). This new formulation, which releases medication in two phases, aims to provide extended relief from GERD symptoms, improving patient compliance and quality of life. The development of this advanced, once-daily tablet underscores Akums’ commitment to offering patient-friendly therapies for chronic acid-related disorders, potentially enhancing its market position in the pharmaceutical industry.
More about Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of innovative drug formulations. The company is known for its advanced pharmaceutical products, particularly in the area of gastroenterology, and aims to address prevalent health conditions through cutting-edge therapies.
Average Trading Volume: 12,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: 72.6B INR
See more insights into AKUMS stock on TipRanks’ Stock Analysis page.